Corvus Pharmaceuticals (NASDAQ:CRVS) Insider Jeffrey Arcara Buys 1,003 Shares of Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) insider Jeffrey Arcara purchased 1,003 shares of the stock in a transaction on Friday, November 13th. The shares were purchased at an average price of $10.54 per share, for a total transaction of $10,571.62. Following the transaction, the insider directly owned 4,500 shares of the company’s stock, valued at approximately $47,430. This represents a 28.68% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Jeffrey Arcara also recently made the following trade(s):

  • On Thursday, November 12th, Jeffrey Arcara purchased 497 shares of Corvus Pharmaceuticals stock. The shares were acquired at an average price of $11.12 per share, for a total transaction of $5,526.64.
  • On Wednesday, November 11th, Jeffrey Arcara bought 3,000 shares of Corvus Pharmaceuticals stock. The shares were acquired at an average cost of $11.46 per share, for a total transaction of $34,380.00.

Corvus Pharmaceuticals Stock Up 0.2%

Shares of CRVS traded up $0.02 during trading hours on Friday, hitting $10.64. The company had a trading volume of 620,431 shares, compared to its average volume of 1,017,570. The firm has a market cap of $897.52 million, a P/E ratio of -14.99 and a beta of 1.57. The stock’s 50 day moving average price is $11.18 and its 200 day moving average price is $14.04. Corvus Pharmaceuticals, Inc. has a 52-week low of $6.39 and a 52-week high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, research analysts expect that Corvus Pharmaceuticals, Inc. will post -0.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CRVS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research report on Monday, October 26th. Ladenburg Thalmann & Co. Inc. raised Corvus Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, July 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, September 16th. Mizuho set a $27.00 price target on Corvus Pharmaceuticals in a report on Thursday, October 29th. Finally, Wall Street Zen lowered Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.83.

Check Out Our Latest Research Report on Corvus Pharmaceuticals

Institutional Trading of Corvus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in CRVS. The Manufacturers Life Insurance Company boosted its holdings in shares of Corvus Pharmaceuticals by 481.7% during the 1st quarter. The Manufacturers Life Insurance Company now owns 101,779 shares of the company’s stock valued at $1,489,000 after acquiring an additional 84,282 shares during the last quarter. DCF Advisers LLC bought a new stake in shares of Corvus Pharmaceuticals in the second quarter worth approximately $9,524,000. Blue Owl Capital Holdings LP purchased a new position in shares of Corvus Pharmaceuticals during the second quarter valued at approximately $9,092,000. Renaissance Technologies LLC purchased a new position in shares of Corvus Pharmaceuticals during the first quarter valued at approximately $1,190,000. Finally, Seven Fleet Capital Management LP purchased a new position in shares of Corvus Pharmaceuticals during the second quarter valued at approximately $1,238,377. 46.64% of the stock is currently owned by hedge funds and other institutional investors.

Key Corvus Pharmaceuticals News

Here’s some of the latest news about CRVS:

  • Positive Sentiment: A Globe and Mail headline includes Corvus among healthcare stocks analysts are bullish on, though the article details provided do not specify a rating or price target. Analysts Are Bullish on Top Healthcare Stocks: Corvus Pharmaceuticals (CRVS), Achieve Life Sciences (QUIT)
  • Negative Sentiment: HC Wainwright cut estimates across multiple periods. It now expects a $1.04-per-share loss in 2027, versus its prior $0.80 loss estimate, and a $0.90 loss in 2028, versus $0.37 previously. It also reduced its 2029 forecast from near breakeven to a $0.43 loss and lowered its 2030 profit estimate to $0.45 from $0.67. The revisions suggest a slower improvement in earnings and could weigh on investor sentiment. HC Wainwright earnings estimate updates

About Corvus Pharmaceuticals

(Get Free Report)

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.

See Also

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.